On February 19, 2025 Reverb Therapeutics, a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, reported it has closed a USD $12 Million financing led by founding investor Amplitude Ventures (Press release, Reverb Therapeutics, FEB 19, 2025, View Source [SID1234650396]). Other participants in the round include the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, InBC Investment Corp. (InBC), and Seido Capital.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Reverb’s novel Amplify•R platform combines bispecific antibody engineering with data-driven modelling of antibody interactions to modulate the actions of endogenous cytokines and redirect them to tissues of interest. This approach avoids the hurdles that have blocked other attempts to enlist cytokines to treat disease, which include systemic toxicity, immunogenicity, and manufacturing issues. Reverb’s initial focus is on the treatment of cancer and autoimmune diseases.
In vivo preclinical studies have established proof-of-concept for the Amplify•R platform’s ability to redirect endogenous cytokines and shrink tumors. The data supports a growing body of evidence for the potency of bispecific antibodies redirecting cytokines to PD-1-positive cells. Reverb’s lead AMP01 program blocks PD-1 while delivering endogenous IL-15, a key protein that expands and activates cytotoxic T cells.
"We are excited to have the backing of this standout group of investors as we advance the Amplify•R platform," said David de Graaf, Ph.D., CEO of Reverb Therapeutics. "The Amplify•R platform has broad potential across many cytokines. With this funding, we will take our lead IL-15 bispecific program to the candidate stage and will develop additional bispecific programs spanning other cytokines and additional cellular targets."
"Since its launch, Reverb has made significant progress in demonstrating the superiority of the Amplify•R platform," said Bharat Srinivasa, Ph.D., principal at Amplitude Ventures. "The preclinical data generated to date are extremely exciting and we believe that the Amplify•R platform will enable Reverb to succeed where many attempts using exogenous cytokines ran into insurmountable obstacles."
With the financing complete, Reverb welcomes two new members to its board of directors:
Maude Tessier, Ph.D., is a longtime biopharma executive, two-time chief business officer and an experienced company builder
Stephan Kontos, Ph.D., a biotech executive and entrepreneur, chairs the scientific advisory board at Anokion.